|
|
- 2017
ADAMDEC1蛋白在胶质瘤中的表达及其意义
|
Abstract:
摘要：目的 探讨ADAMDEC1蛋白在胶质瘤中的表达及意义。方法 前瞻性观察82例胶质瘤患者ADAMDE1的表达情况，其中Ⅳ级胶质瘤28例、Ⅲ级胶质瘤26例，设为高级别胶质瘤组；Ⅱ级胶质瘤23例、Ⅰ级胶质瘤5例，设为低级别胶质瘤组；对照组10例脑组织标本为取自重型颅脑外伤行内减压术的正常脑组织。采用qPCR、免疫组化、Western bloting法检测胶质瘤组织中ADAMDEC1的表达；随访调查统计高级别胶质瘤患者、低级别胶质瘤患者的生存周期与组织中ADAMDEC1表达量的相关性。结果 qPCR、免疫组化、Western blotting结果均显示，高级别胶质瘤ADAMDEC1表达明显增高，低级别胶质瘤ADAMDEC1极少表达，对照组脑组织中ADAMDEC1不表达；高级别组与低级别组及对照组脑组织比较，差异有统计学意义(P<0.05)。随访调查显示，高级别胶质瘤患者生存周期明显较低级别胶质瘤患者短，但组织内ADAMDEC1表达量高级别胶质瘤明显高于低级别胶质瘤，差异有统计学意义(χ2=5.031，P<0.05)。结论 ADAMDEC1的表达与胶质瘤肿瘤细胞病理学上的恶性程度及胶质瘤患者预后密切相关，ADAMDEC1可作为胶质瘤恶性程度分级评判及胶质瘤预后情况的指标。
ABSTRACT: Objective To investigate the expression and significance of ADAMDEC1 in glioma. Methods We prospectively observed the expression of ADAMDEC1 in 77 glioma patients, of which 28 cases were grade Ⅳ glioma, 26 were grade Ⅲ glioma (high-grade glioma); of which 23 cases were Grade Ⅱ glioma, 5 were grade Ⅰ glioma (low-grade glioma). For 10 cases in the control group, brain tissue samples were collected from internal decompression patients with heavy traumatic brain injury. The expression of ADAMDEC1 in glioma tissue was detected immunohistochemistry, RT-PCR, and Western blot. With follow-up survey we explored the relationship between the survival time and the expression of ADAMDEC1 in the patients with high-grade gliomas and low-grade gliomas. Results Compared with the low-grade glioma group and the control group, qPCR, immunohistochemistry and Western blotting all showed that the protein and mRNA levels of ADAMDEC1 in high-grade glioma group were significantly increased, while ADAMDEC1 was expressed little in low-grade glioma group and not expressed in control group (P<0.05). The survey results showed that the survival time of high-grade glioma patients was significantly shorter than low-grade glioma patients; however, the expression level of ADAMDEC1 in the high-grade glioma tissue was significantly higher than in low-grade glioma tissue (χ2=5.031, P<0.05). Conclusion The expression of ADAMDEC1 is closely related to the malignant degree of glioma cells and the prognosis of glioma patients. Therefore, ADAMDEC1 can be used as an index to evaluate the malignance degree of glioma and the prognosis of glioma
| [1] | OSTROM QT, GITTLEMAN H, FULOP J, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the united states in 2008-2012[J]. Neuro Oncol, 2015, 17(Suppl 4):iv1-iv62. |
| [2] | 陈万青，郑荣寿，张思维，等. 2012年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2016, 25(1):1-8. |
| [3] | DEN BENT MJ, BRANDES AA, TAPHOORN MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow up of EORTC brain tumor group study 26951[J]. J Clin Oncol, 2013, 31(3):344-350. |
| [4] | VAN DEN BENT MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician？？s perspective[J]. Acta Neuropathol, 2010, 120(3):297-304. |
| [5] | 陈勤. ADAMs在肿瘤发展中的作用及其机制研究进展[J]. 中国癌症杂志, 2008, 18(2):142-146. |
| [6] | WEI S, WHITTAKER CA, XU G, et al. Conservation and divergence of ADAM family proteins in the Xenopus genome[J]. BMC Evol Biol, 2010, 10:211. |
| [7] | WU W, YAO DF.Combined serumHepatoma specific α-fetoprotein and circulating afetoprotein mRNA in diagnosis of hepatocellular carcinoma[J]. Hepatobiliary Pancreatic Dis Int, 2006, 5(4):538. |
| [8] | CROUSER ED, CULVER DA, KNOX KS, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis[J]. Am J Respir Crit Care Med, 2009, 179(10):929-938. |
| [9] | LUND J1, OLSEN OH, S？？RENSEN ES,et al. ADAMDEC1 is a metzincin metalloprotease with dampened proteolytic activity[J]. J Biol Chem, 2013, 288(29):21367-21375. |
| [10] | WU K, LIAO M, LIU B, et al. ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients[J]. Med Oncol, 2011, 28(2):475-480. |
| [11] | CROUSER ED, CULVER DA, KNOX KS, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis[J]. Am J Respir Crit Care Med, 2009, 179(10):929-938. |
| [12] | VAN DEN BENT MJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in lowgrade glioma[J]. NeuroOncol, 2014, 16(12):1570-1574. |
| [13] | XU J, LIU L, ZHENG X, et al. Expression and inhibition of ADAMDEC1 in craniopharyngioma cells[J]. Neurol Res, 2012, 34(7):701-706. |
| [14] | LOUIS DN, OHGAKI H, WIESTLER OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2):97-109. |
| [15] | CROUSER ED, CULVER DA, KNOX KS, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis[J]. Am J Respir Crit Care Med, 2009, 179(10):929-938. |
